ArticleInternational journal of general medicine2025
Predictive Factors for Fetal Growth Restriction in Patients with Preeclampsia: A Clinical Prediction Study.
Article in International journal of general medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Development and internal validation of a nomogram for predicting adverse pregnancy outcomes in women with early-onset preeclampsia.Frontiers in medicine · 2026Article
- Correlation Between Immune-Inflammatory Biomarkers During Pregnancy and Postpartum and Adverse Outcomes of Preeclampsia: A Longitudinal Retrospective Analysis.Journal of inflammation research · 2025Article
- Serum uric acid as a diagnostic biomarker for preeclampsia: comparison with renal indices and cerebroplacental ratio.Frontiers in endocrinology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Preeclampsia (PE) is a significant pregnancy complication associated with adverse maternal and fetal outcomes, particularly fetal growth restriction (FGR). Identifying risk factors for FGR in PE patients can facilitate timely management and improve neonatal outcomes. Methods: This retrospective case-control study analyzed 714 singleton pregnancies complicated by preeclampsia at Fujian Maternity and Child Health Hospital from January 2016 to October 2023. Participants were categorized based on the presence of FGR. Clinical data, including demographic characteristics, laboratory parameters, intrapartum complications and neonatal outcomes, were collected and analyzed. We employed least absolute shrinkage and selection operator (LASSO) logistic regression to identify independent risk factors for FGR. An individualized predictive nomogram was then developed and validated using a training (499 participants) and a validation cohort (215 participants). The model's discrimination, clinical usefulness, and calibration were assessed using the area under the receiver operating characteristic (ROC) curve, decision curve, and calibration analysis. Results: The study identified 256 women with FGR and 458 without FGR.The research identified nine significant predictors for FGR in PE patients, including family history of hypertension, aspartate aminotransferase (AST), uric acid (URIC), mode of delivery, mean platelet volume (MPV), prothrombin time (PT), severity of preeclampsia, post-pregnancy weight, and gestational age. The nomogram demonstrated excellent predictive performance, with an area under the ROC curve (AUC) of 0.93 (95% CI 0.91-0.96) in the training cohort and 0.90 (95% CI 0.85-0.95) in the validation cohort. Calibration plots indicated that predicted probabilities closely matched observed outcomes in both cohorts, while decision curve analysis (DCA) indicated that the nomogram provided a satisfactory net benefit for patients at risk of FGR. Conclusion: The nomogram developed in this study serves as a reliable tool for predicting FGR in pregnant individuals with preeclampsia. Its application could enhance clinical decision-making and improve fetal outcomes in at-risk populations. Further validation in diverse populations is recommended to strengthen its clinical utility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.